nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-981150AD·Framework v5.0·Pipeline v0.4·Evaluated 17 Jun 2026·OECD: 3.2 Clinical medicine·Subfield: Oncology·Basis: Full text·Type: Randomized controlled trial

Adjuvant Chemotherapy +/- Chemoradiotherapy for Adenocarcinoma of The Pancreatic Head: Results of The Radiotherapy Randomization of NRG Oncology/RTOG 0848

Ross A Abrams et al.Ross A Abrams, Kathryn Winter, Karyn A. Goodman et al.·2026·10.1200/jco-25-02520 ↗

In brief

A rigorously quality-assured phase III trial that definitively shows no overall survival benefit from adjuvant chemoradiotherapy, constrained by its obsolete gemcitabine-era chemotherapy backbone.

ReliabilityConcerns4 of 4 checks completeRead the 3 entries ↓
Abstract

Purpose Whether adding fluoropyrimidine sensitized radiotherapy (CXRT) to adjuvant chemotherapy improves overall survival after curative intent resection of the pancreatic head. Methods A multi-center, randomized phase III, 2 step trial. Step 1: gemcitabine vs. gemcitabine+erlotinib (previously reported). Step 2: randomization to 6 th chemo cycle +/-CXRT after 5 cycles of step 1 chemotherapy without progression. Outcomes of Step 2 randomization are reported here. Assuming 17 months median OS (chemotherapy alone), sample size was 354 patients (HR=0.76, 80% power, 1-sided α=0.05, 316 OS events). OS/DFS were estimated by Kaplan-Meier and arms compared using log-rank test. Results 354 patients (median age 63, 55% male, 56% PS 1) were randomized to chemotherapy(174) or chemotherapy+CXRT(180). Univariate median and 5-year OS (90% CIs) were 2.6 years (2.1-3.1) and 23.1% (17.7-28.6) for chemotherapy alone, and 2.3 years (2.0-2.6) and 27.9% (22.2-33.6) for chemotherapy+CXRT. The OS primary endpoint was not met (HR 0.96, 90% CI: 0.79–1.18, 1-sided p=0.38, 2-sided p=0.77). Chemotherapy+CXRT was associated with a trend for improved DFS (univariately) (HR 0.82, 95% CI: 0.65-1.03, p=0.089), without increase in grade 4/5 toxicities. However, grade 3 toxicity increased (38% vs. 19%, p<0.001). Significantly, treatment by nodal status interactions showed that CXRT improved OS (p=0.0063) and DFS (p=0.014) in node negative patients. Conclusion Overall, the addition of adjuvant CXRT to adjuvant gemcitabine did not statistically significantly improve OS, DFS, or increase grade 4/5 toxicity. For node negative patients, CXRT improved OS and DFS. These results, if confirmed in studies with current or future systemic therapies, would support the use of adjuvant/ neoadjuvant CXRT for node negative patients.

Strengths · Limitations

Strengths

#methodological rigour

Rigorous real-time radiotherapy quality assurance

Participating centers were credentialed and every radiotherapy plan underwent real-time central review before treatment, with reported per-protocol compliance of 92% among treated patients. This directly addresses the quality-assurance weakness of prior negative trials.

↳ Methods—Interventions; Results—Patients and treatment; Data Supplement Table S2

#contribution

Definitive null result on a contested question

The well-powered intention-to-treat analysis shows no overall survival benefit (HR 0.96, 90% CI 0.79-1.18), reinforced by a concordant as-treated sensitivity analysis (HR 0.98). This resolves a long-standing controversy for unselected patients.

↳ Results—Outcomes; Figure 2A

#application pathway

Actionable, specific clinical decision context

The trial targets an explicit decision faced by multidisciplinary teams managing resected pancreatic head cancer, with clearly identifiable stakeholders and direct relevance to current guideline pathways.

↳ Introduction; Discussion; Context Summary

Limitations

#contribution

Outdated chemotherapy backbone limits relevance

All patients received gemcitabine-based chemotherapy and none received FOLFIRINOX/mFOLFIRINOX, which is now preferred for fit patients. This is the central constraint on the generalizability of the findings to current practice.

↳ Table 1; Discussion

#reporting

Affirmative message rests on small subgroup

The practice-supporting node-negative finding derives from a treatment-by-nodal-status interaction in only 91 node-negative patients within a trial whose overall primary endpoint was null. Some conclusion language presents this more strongly than the evidence supports.

↳ Results—Multivariable; Conclusions; Figure 4

#methodological rigour

Reduced statistical power and treatment refusal

Analysis was triggered at five years of follow-up before reaching the planned 316 events, leaving 270 events and power of 72%, and 14% of the chemoradiotherapy arm did not receive the assigned treatment. These factors lower inferential strength for secondary and subgroup interpretations.

↳ Statistical Analysis; Results—Patients and treatment; Discussion

Does this match your read? Add your assessment ↓

Nabu Commentary

The adjudicated scores reflect a competently executed cooperative-group phase III trial whose strongest firm conclusion is negative: adding chemoradiotherapy to gemcitabine-based adjuvant therapy did not improve overall survival, supported by an intention-to-treat analysis and a concordant as-treated sensitivity analysis. Methodological Rigour is anchored by the real-time central radiotherapy quality assurance and transparent handling of two protocol amendments, while precision is tempered by the open-label design, 14% treatment refusal, and reduced realized event count. Contribution is held below the top band because the affirmative node-negative signal arises from an interaction term in only 91 patients and because the gemcitabine-era backbone no longer reflects standard care. The reliability picture is Amber rather than Green because several conclusion statements frame the node-negative benefit as supporting clinical use, a stronger position than the null primary endpoint and the paper's own repeated calls for confirmation warrant.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.9±0.1

Contribution
3.7

The trial delivers a well-powered, definitive null result for adjuvant CXRT in unselected resected pancreatic head adenocarcinoma plus a hypothesis-generating node-negative interaction, advancing a decades-long controversy. The contribution is bounded by the negative primary endpoint and an outdated gemcitabine-based comparator that no longer reflects standard care.

Results—Outcomes; Results—Multivariable; Discussion

the addition of adjuvant CXRT to adjuvant gemcitabine did not statistically significantly improve OS

Methodological Rigour
4.0

Execution is strong: central stratified randomization, ITT primary analysis with a concordant as-treated sensitivity analysis, real-time central radiotherapy quality assurance, systematic CTCAE v4.0 harms reporting, and transparent protocol amendments. Open-label design, 14% CXRT refusal, and reduced realized events (270 vs 316, power to 72%) temper precision without invalidating the null result.

Statistical Analysis; Results—Patients and treatment; Table 2; Discussion

an OS "as treated" sensitivity analysis ... results were very similar to the ITT analysis

Reporting
4.0

The manuscript is logically structured and reports both one-sided and two-sided p-values with an explicit statement that the primary endpoint was not met. Some conclusion sentences frame the node-negative benefit more strongly than the trial's own 'if confirmed' caveat supports.

Abstract; Results—Outcomes; Conclusions

do support the use of adjuvant CXRT for node negative patients

Positioning
4.0

The paper engages substantively with ESPAC-1, RTOG 9704, and the FOLFIRINOX-era adjuvant literature and contrasts its quality-assured radiotherapy against the methodological weaknesses of prior negative trials. Its final positioning of node-negative benefit edges slightly beyond what a null-primary trial securely establishes.

Introduction; Discussion

In ESPAC-1 CXRT was detrimental, but herein, it improved outcomes for selected patients

Reliability

Concerns4 of 4 checks


Internal CoherenceNoted

The null overall primary endpoint and the node-negative subgroup interaction are reported consistently across abstract, results, and discussion, but some concluding statements assert the data 'do support the use' of adjuvant CXRT for node-negative patients, which is stronger than the paper's own repeated 'if confirmed' hedging given a null primary trial and a small subgroup.

Research ConductNoted

The trial is prospectively registered (NCT01013649), reports central randomization, written informed consent, IRB approval per NCTN procedures, CONSORT reporting, and central radiotherapy quality assurance; ethics approval is declared in general terms without an independently verifiable identifier, and no data or code availability statement is present in the provided manuscript text.

Flags: 2 declared / 5 total

Reference IntegrityNoted

1 of 7 cited references could not be verified as real publications, exceeding the threshold for reliable citation. See list.

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Cancer and neoplasms · Pancreatic cancer
Type of advanceEmpirical
Route to useSuggested
AdvanceAdvances
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

A multi-center randomized phase III trial of 354 patients across many sites in the US, Canada, and Israel directly tested the primary overall-survival question, though the node-negative benefit remains an unconfirmed subgroup finding.

From the paper
“These results, if confirmed in studies with current or future systemic therapies, would support the use of adjuvant/ neoadjuvant CXRT for node negative patients.”

The paper names a concrete real-world use (adjuvant or neoadjuvant chemoradiotherapy for node-negative patients) but does not name who would act on or deliver it.

Pathway

Radiation and medical oncologists could add chemoradiotherapy for node-negative resected pancreatic head cancer patients, and trial groups would first confirm this with modern systemic therapies.

Barrier

The node-negative benefit is a subgroup finding that requires independent confirmation with modern systemic therapies like FOLFIRINOX, which has replaced gemcitabine as standard adjuvant treatment.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity

    Mateusz Kciuk, Adrianna Gielecińska, Somdutt Mujwar, et al. · 2023 · Clinical medicine

    Primary claim

    Emerging evidence points to the pleiotropic anticancer activity of DOX, including its contribution to DNA damage, reactive oxygen species production, apoptosis, senescence, autophagy, ferroptosis, and pyroptosis induction, as well as its immunomodulatory role.

    Supported
    Evidence Score
    3.1±0.2
    Reliability
    Caveats
  2. Osteonecrosis of the jaw associated with ziv-aflibercept

    Hani Mawardi, Peter Enzinger, Nadine J. McCleary, et al. · 2016 · Clinical medicine

    Evidence Score
    3.4±0.1
    Reliability
    Caveats
  3. Prognosis of locally advanced rectal cancer can be predicted more accurately using pre- and post-chemoradiotherapy neutrophil-lymphocyte ratios in patients who received preoperative chemoradiotherapy

    Sung, Son, Park, et al. · 2017 · Clinical medicine

    Evidence Score
    3.1±0.2
    Reliability
    Caveats

How the rubric works →